Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003